focus -WSS

focus

author：entertainment 2025-10-01 20:15:29 - browse：1

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Why hospitals are withdrawing from US News rankings

explore

WSS

With psoriasis trial ahead, Alumis raises $259 million

NEJM study link tiny plastics in blood vessels to heart problems

RSV shot was 90% effective at preventing hospitalizations in kids

IVF, abortion rights issues kick off Biden’s State of the Union

CDC marks new Covid

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Peter Hotez and the public health issue of online harassment

What it’s like to watch children die of measles

Wildfire smoke exposes gaps in outdoor worker protections

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

FDA approval of Sarepta Duchenne genetic therapy gives me hope

In early work, researchers turn to CRISPR to treat Alzheimer's

In Memoriam: Notable people who died in 2023

In early work, researchers turn to CRISPR to treat Alzheimer's

Medical records are filled with copy

In early work, researchers turn to CRISPR to treat Alzheimer's

hotspot

As digital health tech proliferates, a new institute aims to cut through hype

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Change Healthcare cyberattack prompts Medicare loan program

UnitedHealth quietly bought dozens of outpatient centers

FDA approves RSV monoclonal antibody for infants, toddlers

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

knowledge

explore

explore

hotspot